Prehabilitation in Rectal Cancer: During Neoadjuvant Therapy vs Preoperative (PREHAREC)
Primary Purpose
Rectal Cancer, Adenocarcinoma, Chemoradiotherapy
Status
Not yet recruiting
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
prehabilitation
Sponsored by
About this trial
This is an interventional other trial for Rectal Cancer, Adenocarcinoma focused on measuring RECTAL CANCER, PREAHBILITATION, NEOADJUVANCY, COMPREHENSION COMPLICATION INDEX
Eligibility Criteria
Inclusion Criteria:
- Patient with rectal tumour and selected to initiate NRCT
- Patient must know the study and sign informed consent.
- Patient must accept the conditions necessaries to carry out the prehabilitation.
Exclusion Criteria:
- Refusal of the patient to sign the informed consent.
- Baseline pathology that makes it impossible to carry out prehabilitation.
- Progression of the disease during the study period.
- Emergency surgery.
Sites / Locations
- Laura Mora López
Arms of the Study
Arm 1
Arm 2
Arm Type
Sham Comparator
Experimental
Arm Label
PREHAB-PREOP
PREHAB-NEOADJ
Arm Description
PREHABILITATION BEFORE SURGERY
PREHABILITATION DURING NEOADJUVANCY AND BEFORE SURGERY
Outcomes
Primary Outcome Measures
Comprehension Complication Index (CCI)
Morbidity after surgery of rectal cancer: CCI - value 0-100
Secondary Outcome Measures
6 minutes walking test (6MWT)
Walking test that helps calculation of the number of daily steps to be carried out (5.000 to 10.000) daily steps
Hospital Anxiety and Depression Scale (HADS) test : anxious and depresion scale
Calculation of level of anxiety or depression in mild, moderate or severe. Allows referral of the patient to the psychology service
Full Information
NCT ID
NCT05286086
First Posted
February 9, 2022
Last Updated
March 17, 2022
Sponsor
Corporacion Parc Tauli
1. Study Identification
Unique Protocol Identification Number
NCT05286086
Brief Title
Prehabilitation in Rectal Cancer: During Neoadjuvant Therapy vs Preoperative
Acronym
PREHAREC
Official Title
Randomized Controlled Trial Comparing the Effect of a Multimodal Prehabilitation Program During Neoadjuvant Treatment Versus a Multimodal Prehabilitation After Neoadjuvant Treatment for Patients Undergoing Resection of Rectal Cancer.
Study Type
Interventional
2. Study Status
Record Verification Date
March 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
March 2022 (Anticipated)
Primary Completion Date
March 2022 (Anticipated)
Study Completion Date
March 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Corporacion Parc Tauli
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Control of the effect of prehabilitation on postoperative morbidity, assessed by the Comprehensive Complication Index (CCI), in patients diagnosed with rectal cancer that will receive neoadjuvant Quimiorradiotherapy (NCRT) and subsequent surgery, performed at the beginning of NCRT or before surgery.
Detailed Description
According to the annual report of the Spanish Medical Oncology Association (SEOM), in Spain and without differentiating by sex, colorectal cancer will be the cancer with the highest incidence by 2021; with 43.581 new cases estimated for such year, 14.209 of these will be of rectal cancer. In rectal cancer, surgery remains the cornerstone; however, it is already known that local recurrences are frequent. That is why one of the main milestones rectal cancer treatment, is the multimodal therapy approach. It consists of implementing a neoadjuvant chemoradiotherapy treatment (NCRT) prior to surgical intervention. With this, local control of the disease is achieved, metastases are reduced have resulted in a five-year survival. Subsequently, depending on the definitive pathological results, patients should also complete treatment with postoperative chemotherapy. It is known that patients undergoing neoadjuvant treatment experience a wide variety of side effects, which can cause loss of muscle and cardiovascular function, loss of their functional capacity and increased fatigue. This worsens the quality of life of the patient and can sometimes cause the interruption of neoadjuvant treatment and have repercussions on the prognosis. Not only do these side effects affect the course of neoadjuvant treatment, but also declines the physiological reserve, making the patient arrive in sub-optimal conditions for surgery. This has an impact on postoperative morbidity and mortality, and secondarily, in the increase of hospital stay.
The concept of functional capacity appears ¨as the nutritional, physical and emotional state that a person has to face a stressful situation, such as surgical treatment. It is believed that if functional capacity is enhanced, postoperative morbidity can be reduced and the patient's recovery can also be improved. That is why trimodal programs are created, specifically selected for their potential cumulative or synergistic effects on health outcomes to prepare patients to face surgery at all three levels. These programs are known as prehabilitation.
Currently there are studies that show that prehabilitation improves the results of patients who must undergo different major surgical procedures, among them in colorectal surgery. Our group has recently presented a study that shows that trimodal prehabilitation contributes to reducing postoperative morbidity and overall hospital stay in patients operated on for colorectal neoplasia. There are also systematic reviews that conclude that prehabilitated patients who must undergo major surgery (speaking of 435 patients and 9 studies) present a decrease in the incidence of major postoperative complications. On the other hand, there are studies that show that prehabilitation in patients who must receive neoadjuvant therapy reduces the decrease of functional capacity that treatment produces on patients. As also shown by the Rex Trial, a randomized study on 48 patients. In an attempt to unite the two lines start the study, it will be a novel one , with only two previously published studies in this area. The intention is demonstrate that when prehabilitation is started before commencing neoadjuvant therapy in patients who are diagnosed with rectal cancer and who are subject to neoadjuvant therapy, will reduce the effect on functional capacity, and that patients will present less postoperative morbidity and better postoperative recovery.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rectal Cancer, Adenocarcinoma, Chemoradiotherapy
Keywords
RECTAL CANCER, PREAHBILITATION, NEOADJUVANCY, COMPREHENSION COMPLICATION INDEX
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Prospective , unicentric, randomized
Masking
None (Open Label)
Masking Description
due to the characteristics of the study, it is not possible to perform masking
Allocation
Randomized
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
PREHAB-PREOP
Arm Type
Sham Comparator
Arm Description
PREHABILITATION BEFORE SURGERY
Arm Title
PREHAB-NEOADJ
Arm Type
Experimental
Arm Description
PREHABILITATION DURING NEOADJUVANCY AND BEFORE SURGERY
Intervention Type
Behavioral
Intervention Name(s)
prehabilitation
Intervention Description
Control of the physical, nutritional and psychological preparation of the patient who will undergo rectal cancer surgery
Primary Outcome Measure Information:
Title
Comprehension Complication Index (CCI)
Description
Morbidity after surgery of rectal cancer: CCI - value 0-100
Time Frame
through study completion, an average of 1 yea
Secondary Outcome Measure Information:
Title
6 minutes walking test (6MWT)
Description
Walking test that helps calculation of the number of daily steps to be carried out (5.000 to 10.000) daily steps
Time Frame
through study completion, an average of 1 yea
Title
Hospital Anxiety and Depression Scale (HADS) test : anxious and depresion scale
Description
Calculation of level of anxiety or depression in mild, moderate or severe. Allows referral of the patient to the psychology service
Time Frame
through study completion, an average of 1 yea
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient with rectal tumour and selected to initiate NRCT
Patient must know the study and sign informed consent.
Patient must accept the conditions necessaries to carry out the prehabilitation.
Exclusion Criteria:
Refusal of the patient to sign the informed consent.
Baseline pathology that makes it impossible to carry out prehabilitation.
Progression of the disease during the study period.
Emergency surgery.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Laura Mora
Phone
34 937211010
Ext
21490
Email
mora.lopez.laura@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Laura Mora, Dr
Phone
34 937211010
Ext
21490
Email
mora.lopez.laura@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Laura Mora, Dr
Organizational Affiliation
Parc Tauli University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Laura Mora López
City
Sabadell
State/Province
Barcelona
ZIP/Postal Code
08208
Country
Spain
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laura Mora, Dr.
Phone
34639101033
Email
mora.lopez.laura@gmail.com
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
25629513
Citation
Berho M, Narang R, Van Koughnett JA, Wexner SD. Modern multidisciplinary perioperative management of rectal cancer. JAMA Surg. 2015 Mar 1;150(3):260-6. doi: 10.1001/jamasurg.2014.2887.
Results Reference
result
PubMed Identifier
23058059
Citation
Herman JM, Narang AK, Griffith KA, Zalupski MM, Reese JB, Gearhart SL, Azad NS, Chan J, Olsen L, Efron JE, Lawrence TS, Ben-Josef E. The quality-of-life effects of neoadjuvant chemoradiation in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):e15-9. doi: 10.1016/j.ijrobp.2012.09.006. Epub 2012 Oct 9.
Results Reference
result
PubMed Identifier
23008766
Citation
Pramateftakis MG, Kanellos D, Tekkis PP, Touroutoglou N, Kanellos I. Rectal cancer: multimodal treatment approach. Int J Surg Oncol. 2012;2012:279341. doi: 10.1155/2012/279341. Epub 2012 Sep 12. No abstract available.
Results Reference
result
PubMed Identifier
30025745
Citation
Gillis C, Fenton TR, Sajobi TT, Minnella EM, Awasthi R, Loiselle SE, Liberman AS, Stein B, Charlebois P, Carli F. Trimodal prehabilitation for colorectal surgery attenuates post-surgical losses in lean body mass: A pooled analysis of randomized controlled trials. Clin Nutr. 2019 Jun;38(3):1053-1060. doi: 10.1016/j.clnu.2018.06.982. Epub 2018 Jul 9.
Results Reference
result
PubMed Identifier
27536795
Citation
Wright S, Wiechula R, McLiesh P. The effectiveness of prehabilitation for adults having elective surgery: a systematic review protocol. JBI Database System Rev Implement Rep. 2016 Feb;14(2):78-92. doi: 10.11124/jbisrir-2016-2460. No abstract available.
Results Reference
result
PubMed Identifier
33505914
Citation
Santa Mina D, van Rooijen SJ, Minnella EM, Alibhai SMH, Brahmbhatt P, Dalton SO, Gillis C, Grocott MPW, Howell D, Randall IM, Sabiston CM, Silver JK, Slooter G, West M, Jack S, Carli F. Multiphasic Prehabilitation Across the Cancer Continuum: A Narrative Review and Conceptual Framework. Front Oncol. 2021 Jan 11;10:598425. doi: 10.3389/fonc.2020.598425. eCollection 2020.
Results Reference
result
Learn more about this trial
Prehabilitation in Rectal Cancer: During Neoadjuvant Therapy vs Preoperative
We'll reach out to this number within 24 hrs